Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation

Maria Teresa Lupo-Stanghellini, Elena Provasi, Attilio Bondanza, Fabio Ciceri, Claudio Bordignon, Chiara Bonini

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most serious and frequent complication of allo-SCT: graft-versus-host-disease (GvHD). The risk of GvHD increases with the level of HLA disparity between host and donor, and leads to impaired quality of life and reduced survival expectancy, particularly among patients receiving transplants from HLA-mismatched donors. Gene transfer technologies are promising tools to manipulate donor T cell immunity to enforce the graft-versus-tumor effect, to promote functional immune reconstitution (graft vs. infection), and to prevent or control GvHD. To this purpose, several cell and gene transfer approaches have been investigated at the preclinical level, and are being implemented in clinical trials. Suicide gene therapy is to date the most extensive clinical application of T cell-based gene therapy. In several phase I-II clinical studies conducted worldwide this approach proved highly feasible, safe, and effective in promoting a dynamic and patient-specific modulation of alloreactivity. This review focuses on this approach.

Original languageEnglish
Pages (from-to)241-250
Number of pages10
JournalHuman Gene Therapy
Volume21
Issue number3
DOIs
Publication statusPublished - Mar 1 2010

Fingerprint

Hematopoietic Stem Cell Transplantation
Genetic Therapy
Suicide
Tissue Donors
Graft vs Host Disease
Transplants
Minor Histocompatibility Antigens
Technology Transfer
T-Lymphocytes
Unrelated Donors
Hematologic Diseases
Fetal Blood
Immunotherapy
Genes
Immunity
Neoplasms
Transplantation
Quality of Life
Clinical Trials
Lymphocytes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. / Lupo-Stanghellini, Maria Teresa; Provasi, Elena; Bondanza, Attilio; Ciceri, Fabio; Bordignon, Claudio; Bonini, Chiara.

In: Human Gene Therapy, Vol. 21, No. 3, 01.03.2010, p. 241-250.

Research output: Contribution to journalArticle

Lupo-Stanghellini, Maria Teresa ; Provasi, Elena ; Bondanza, Attilio ; Ciceri, Fabio ; Bordignon, Claudio ; Bonini, Chiara. / Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. In: Human Gene Therapy. 2010 ; Vol. 21, No. 3. pp. 241-250.
@article{60fd40654c1549c69304a424f8f2c77e,
title = "Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most serious and frequent complication of allo-SCT: graft-versus-host-disease (GvHD). The risk of GvHD increases with the level of HLA disparity between host and donor, and leads to impaired quality of life and reduced survival expectancy, particularly among patients receiving transplants from HLA-mismatched donors. Gene transfer technologies are promising tools to manipulate donor T cell immunity to enforce the graft-versus-tumor effect, to promote functional immune reconstitution (graft vs. infection), and to prevent or control GvHD. To this purpose, several cell and gene transfer approaches have been investigated at the preclinical level, and are being implemented in clinical trials. Suicide gene therapy is to date the most extensive clinical application of T cell-based gene therapy. In several phase I-II clinical studies conducted worldwide this approach proved highly feasible, safe, and effective in promoting a dynamic and patient-specific modulation of alloreactivity. This review focuses on this approach.",
author = "Lupo-Stanghellini, {Maria Teresa} and Elena Provasi and Attilio Bondanza and Fabio Ciceri and Claudio Bordignon and Chiara Bonini",
year = "2010",
month = "3",
day = "1",
doi = "10.1089/hum.2010.014",
language = "English",
volume = "21",
pages = "241--250",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation

AU - Lupo-Stanghellini, Maria Teresa

AU - Provasi, Elena

AU - Bondanza, Attilio

AU - Ciceri, Fabio

AU - Bordignon, Claudio

AU - Bonini, Chiara

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most serious and frequent complication of allo-SCT: graft-versus-host-disease (GvHD). The risk of GvHD increases with the level of HLA disparity between host and donor, and leads to impaired quality of life and reduced survival expectancy, particularly among patients receiving transplants from HLA-mismatched donors. Gene transfer technologies are promising tools to manipulate donor T cell immunity to enforce the graft-versus-tumor effect, to promote functional immune reconstitution (graft vs. infection), and to prevent or control GvHD. To this purpose, several cell and gene transfer approaches have been investigated at the preclinical level, and are being implemented in clinical trials. Suicide gene therapy is to date the most extensive clinical application of T cell-based gene therapy. In several phase I-II clinical studies conducted worldwide this approach proved highly feasible, safe, and effective in promoting a dynamic and patient-specific modulation of alloreactivity. This review focuses on this approach.

AB - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most serious and frequent complication of allo-SCT: graft-versus-host-disease (GvHD). The risk of GvHD increases with the level of HLA disparity between host and donor, and leads to impaired quality of life and reduced survival expectancy, particularly among patients receiving transplants from HLA-mismatched donors. Gene transfer technologies are promising tools to manipulate donor T cell immunity to enforce the graft-versus-tumor effect, to promote functional immune reconstitution (graft vs. infection), and to prevent or control GvHD. To this purpose, several cell and gene transfer approaches have been investigated at the preclinical level, and are being implemented in clinical trials. Suicide gene therapy is to date the most extensive clinical application of T cell-based gene therapy. In several phase I-II clinical studies conducted worldwide this approach proved highly feasible, safe, and effective in promoting a dynamic and patient-specific modulation of alloreactivity. This review focuses on this approach.

UR - http://www.scopus.com/inward/record.url?scp=77949768669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949768669&partnerID=8YFLogxK

U2 - 10.1089/hum.2010.014

DO - 10.1089/hum.2010.014

M3 - Article

VL - 21

SP - 241

EP - 250

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -